Hallenstein Glasson Holdings Limited provides the attached Capital Change Notice pursuant to NZX Listing Rule 3.13.1. This notice relates to the issue of 36,873 performance share rights to the Group CEO under the Hallenstein Glasson Holdings Limited Long Term
Incentive Plan.
Auckland surgical products company is forecasting annual profit of between $2m to $6m.
The cancer diagnostics company is awaiting outcomes of several events.
Software firm won't pay dividend as it plans for more growth in consolidating markets.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details